Coronavirus: an american vaccine will be tested on 30 000 volunteers, from July

Coronavirus: un vaccin américain sera testé sur 30 000 volontaires à partir de juillet

The experimental vaccine against the COVID-19 biotech american Moderna, co-funded by the us government, will come in the third and final phase of the clinical trial in July on 30 000 volunteers, the company announced Thursday.

This is the decisive phase of testing, which will see, over a large sample of healthy persons, the vaccine is more effective than a placebo to prevent contamination by the new coronavirus. The protocol has been finalised with the us Agency of drugs (FDA), and the trial will be conducted in collaboration with the national Institutes of health (NIH).

Moderna is with the university of Oxford, which has also launched a large-scale test on 10 000 volunteers and expects first results in September, part one of the first in the global race to the vaccine. The biotech has received 483 million dollars from the u.s. government. It announced on may 18, the first encouraging results on a small number of volunteers (eight), in the framework of the first phase of clinical trials.

Phase 2, which will include 600 volunteers, began in late may. The vaccination consists of two doses separated by 28 days. Half of the participants receives a placebo, in a random way.

If the dose chosen for testing (100 micrograms) should prove effective, Moderna is expected to be able to produce 500 million doses per year, and ” possibly up to $ 1 billion “.

The company is one of the five companies on which the administration of president Donald Trump would have wagered within the framework of its operation “Warp Speed” (the speed of light), according to the New York Times, with AstraZeneca (industrial partner of the vaccine in Oxford), Johnson & Johnson, Merck, and Pfizer. The aim is to manufacture 300 million doses of vaccine by January 2021.

The technology of Moderna, based on the messenger RNA, has never been shown to be effective against other viruses. It aims to give the body the genetic information needed to trigger preventive protection against the coronavirus.

Share Button